India's drug minister said there was a misconception in the nation--including in its media--that prices of pharmaceuticals had skyrocketed recently. Ananth Kumar noted that 350 additional drugs had been brought under price controls in the past 10 months and other plans are already driving down costs.
Diabetes care at Abbott Laboratories has returned to sales growth as ex-U.S. sales of its new FreeStyle Libre kick in and the impact of diabetes device reimbursement reductions dropped off the books. The continuous glucose monitor eliminates regular finger sticks and has surpassed the company's sales expectations.
Vietnam has become the 39th nation cleared for global exports of the vaccines it makes, joining an increasingly crowded field of local champions to multinational heavyweights. The World Health Organization gave that clearance recently for a country that expects to be a leading producer within the next 20 to 30 years.
A committee of India's parliament voted to bring all drugs sold in the country under price controls determined by the National Pharmaceutical Pricing. The NPPA's reach currently is limited to 509 drugs on the nation's list of essential drugs.
India's Department of Pharmaceuticals could soon get a new name to reflect all of its authority: Department of Pharmaceuticals and Medical Devices. The department is a unit of the Ministry of Chemicals and Fertilisers.
Many of the largest pharmaceutical firms operating in India are contemplating becoming "paper tigers," existing there only on paper, with facilities moved to other countries. Regulatory delays get the blame.
Japan-based Eisai said it has merged its two India subsidiaries, Eisai Pharmaceuticals India based in Mumbai and Eisai Pharmatechnology and Manufacturing based in Visakhapatnam.
India drug authorities plan to impose bar-code rules on single cartons of exported drugs beginning July 1, but have deferred requiring the tags on individual bottles or vials of the products.
India plans to establish a new agency, the Biopharma Industry Incubator, to support healthcare startups in researching and developing new drugs as part of the nation's push to find treatments for its major diseases.
India's Mankind Pharmaceuticals intends to take on the nation's giant drugmakers by spending more than $80 million acquiring local pharmas in niche markets, its managing director said in an interview. It also seeks licensing deals with multinationals, he said.